Risk factors linked to implanted vascular access device migration


#IVTEAM #Intravenous literature: Fan, W.C., Wu, C.H., Tsai, M.J., Tsai, Y.M., Chang, H.L., Yu-Hung, J., Chen, P.H. and Yang, C.J. (2014) Risk factors for venous port migration in a single institute in Taiwan. World Journal of Surgical Oncology. 12(1), P.15.


BACKGROUND: An implantable port device provides an easily accessible central route for long-term chemotherapy. Venous catheter migration is one of the rare complications of venous port implantation. It can lead to side effects such as pain in the neck, shoulder, or ear, venous thrombosis, and even life-threatening neurologic problems. To date, there are few published studies that discuss such complications.

METHODS: This retrospective study of venous port implantation in a single center, a Taiwan hospital, was conducted from January 2011 to March 2013. Venous port migration was recorded along with demographic and characteristics of the patients.

RESULTS: Of 298 patients with an implantable import device, venous port migration had occurred in seven, an incidence rate of 2.3%. All seven were male and had received the Bard port Fr 6.6 which had smaller size than TYCO port Fr 7.5 and is made of silicon. Significantly, migration occurred in male patients (P = 0.0006) and in those with lung cancer (P = 0.004). Multivariable logistic regression analysis revealed that lung cancer was a significant risk factor for port migration (odds ratio: 11.59; P = 0.0059). The migration rate of the Bard port Fr 6.6 was 6.7%. The median time between initial venous port implantation and port migration was 35.4 days (range, 7 to 135 days) and 71.4% (5/7) of patients had port migration within 30 days after initial port implantation.

CONCLUSIONS: Male sex and lung cancer are risk factors for venous port migration. The type of venous port is also an important risk factor.

Main page


Comments are closed.